Maintaining the momentum: Hepatitis C and HIV in the context of harm reduction

September 28, 2022



Today's Panelists

Doug Belanger

Community Support Worker, South Riverdale Community Health Centre

Bernadette Lettner

Nurse, South Riverdale Community Health Centre

Chris Fraser

Medical Director, Victoria Cool Aid Society

Kayla DeMong

Executive Director, Prairie Harm Reduction

Kate Harland

Vice-President, Harm Reduction Nurses Association

Camille Arkell

Manager, HIV and Harm Reduction, CATIE



Today's Agenda

1. Overview: HIV and hepatitis C among people who use drugs Camille Arkell, CATIE

2. Panel discussion: Maintaining the momentum

3. Questions



Today's discussion...

- 1. Social and structural factors: Linking data and practice
- 2. Prevention: A wholistic health approach
- 3. Testing and linkage-to-care: Reaching the undiagnosed
- 4. Treatment: Improving access to care



1. Social and structural factors: Linking data and practice





2. Prevention: A wholistic health approach





3. Testing and linkage-to-care: Reaching the undiagnosed





4. Treatment: Improving access to care





Presented by: Camille Arkell

HIV and hepatitis C among people who use drugs

——— Maintaining the momentum: Hepatitis C and HIV in the context of harm reduction



Why are people who use drugs disproportionately affected by hepatitis C and HIV?

Two infections that are <u>preventable</u> and <u>treatable</u> (or curable in the case of hepatitis C)



Individual risk behaviours

Why are people who use drugs disproportionately affected by hepatitis C and HIV?

Criminalization
Systemic stigma and discrimination impacts SDOH
aring injection
Access to services
Increased social isolation

Social determinants of health

Other contextual factors



Changing drug use patterns impact risk



Increase in injection drug use^{1,2}



Increase in methamphetamine and prescription opioid injection²



Increase in injection drug use equipment sharing ²




Hepatitis C and HIV among people who inject drugs



HIV and hepatitis C among people who inject drugs

HIV

 Out of an estimated 1,520 new HIV infections in Canada in 2020, 22.6% were in people who inject drugs



 An estimated 1 in 10 people who inject drugs was living with HIV (2017-2019)

Hepatitis C


- There were **9,500** new infections in 2019
- An estimated 45% of people who inject drugs in Canada have ever had hepatitis C
- An estimated 1 in 4 people who inject drugs was living with hepatitis C in 2019

Hepatitis C disproportionately affects certain populations and communities.

In 2019, 1 in 4 people who inject drugs was living with chronic hepatitis C.

Regional variation in HIV and hepatitis C

Province/region	Estimated proportion
British Columbia	21.3%
Alberta	20.1%
Saskatchewan	62.6%
Manitoba	60.0%
Ontario	8.3%
Québec	3.4%
Atlantic	13.3%
Territories	Number not reported
Overall (Canada)	19.8%




Continuum of care

Diagnosis


Linkage to care

Successful treatment





HIV continuum of care





Hepatitis C continuum of care

50%

49%

11%

People who inject
drugs who are
diagnosed

Diagnosed people who are linked to hepatitis C care

People linked to care who have taken treatment







Photo by <u>Jon Tyson</u> on <u>Unsplash</u>



References

- Jacka B, Larney S, Degenhardt L, Janjua N, Høj S, Krajden M, Grebely J, Bruneau J. Prevalence of injecting drug use and coverage of interventions to prevent HIV and hepatitis C virus infection among people who inject drugs in Canada. Am J Public Health 2020;110(1):45–50. https://doi.org/10.2105/AJPH.2019.305379
- Lourenço L, Kelly M, Tarasuk J et al. The hepatitis C epidemic in Canada: An overview of recent trends in surveillance, injection drug use, harm reduction and treatment. *Canada Communicable Disease Report*. 2021;47(12):505-14.
- Public Health Agency of Canada. 2022. People living with hepatitis C (HCV) in Canada, 2019.
 https://www.canada.ca/en/public-health/services/publications/diseases-conditions/infographic-people-living-with-hepatitis-c.html
- Public Health Agency of Canada. 2022. Estimates of HIV incidence, prevalence and Canada's progress on meeting the 90-90-90 HIV targets, 2020. https://www.canada.ca/en/public-health/services/publications/diseases-conditions/estimates-hiv-incidence-prevalence-canada-meeting-90-90-90-targets-2020.html
- Tarasuk J, Zhang J, Lemyre A et al. National findings from the Tracks survey of people who inject drugs in Canada, Phase 4, 2017-2019. Canada Communicable Disease Report. 2020;46(5):138-148.
 https://doi.org/10.14745/ccdr.v46i05a07

